JP Morgan Initiates Coverage On C4 Therapeutics with Overweight Rating, Announces Price Target of $10

JP Morgan analyst Anupam Rama has initiated coverage on C4 Therapeutics (NASDAQ: CCCC) with an Overweight rating. The firm has set a price target of $10 for the stock.